...Brigitte Sophia Winkler Background: In KEYNOTE-119 (ClinicalTrials.gov, NCT02555657), overall survival (primary end-point) was similar between pembrolizumab and chemotherapy in patients with previously treated metastatic triple-negative breast cancer (TNBC), although the pembrolizumab treatment...

...Christoph Blazejak; Chalid Assaf Background: Gemcitabine is an effective single-agent chemotherapy used in advanced stages of cutaneous T-cell lymphoma (CTCL). However, gemcitabine used in the current standard regimen is frequently associated with adverse events (AE), such as an increased risk...

... not yet been reported. Methods: The PRAEGNANT registry was used to identify advanced HR + HER2- BC patients (n = 1136). The use of chemotherapy, ET, everolimus + ET, and CDK4/6i + ET was analyzed for first-line, second-line, and third-line therapy. Progression-free survival (PFS) and overall survival (OS...

...Maggie Banys-Paluchowski; Natalia Krawczyk Background: When chemotherapy is indicated in patients with early breast cancer, regimens that contain anthracyclines and taxanes are established standard treatments. Gemcitabine has shown promising effects on the response and prognosis in patients...

.... Literatur 1. Al-Batran SE, Homann N, Pauligk C, Goetze TO et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction...

...Yuka Aida; Kensuke Nakazawa; Toshihiro Shiozawa; Ryoko Ogawa; Takumi Kiwamoto; Yuko Morishima; Ikuo Sekine; Nobuyuki Hizawa Zusammenfassung Das kleinzellige Lungenkarzinom (small-cell lung cancer, SCLC) reagiert sehr empfindlich auf eine platinbasierte Chemotherapie. Bei Patienten, die bei der...

.... Chemotherapies - taxane-based regimens in particular - were associated with in-creased rates of long-term symptoms, including persistent peripheral neuropathy. Overall, the data show a substantial prevalence of a wide variety of potentially treatment-associated symptoms over a protracted time frame after...

...Eugen Ruckhäberle Summary Objective: The primary outcome of the current study is, whether there is a protective effect of prior chemotherapy or of prior granulocyte colony-stimulating factor (G-CSF) on the next cycle blood cell counts. Methods: Hematologic toxicity was evaluated, based...